View Entire Collection
By Clinical Topic
By State Requirement
Diabetes – Summer 2012
Future of Nursing Initiative
Heart Failure - Fall 2011
Influenza - Winter 2011
Nursing Ethics - Fall 2011
Trauma - Fall 2010
Traumatic Brain Injury - Fall 2010
Fluids & Electrolytes
MONDAY, Nov. 16 (HealthDay News) -- In rats induced with type 1 diabetes, topical treatment with naltrexone hydrochloride (NTX), an opioid antagonist, reverses dry eye and restores corneal sensitivity, according to a study in the November issue of the Archives of Ophthalmology.
Ian S. Zagon, Ph.D., of the Pennsylvania State University in Hershey, and colleagues used streptozotocin to induce type 1 diabetes in rats. One group of rats received either NTX eye drops or sterile vehicle once only, while two other groups of rats received either NTX eye drops or sterile vehicle four times a day for one day or five days.
The researchers found that one drop of NTX once only or four times a day for one or five days normalized tear production and corneal sensitivity within one hour of administration. They also found that the effect on tear production persisted for as long as three days and that the effect on corneal sensation persisted for four to seven days.
"This would suggest the need for the initiation of clinical trials examining the safety and efficacy of this drug for ocular use," the authors write. "Moreover, it may be reasonable to evaluate the impact of NTX on other non-ocular complications of diabetes, such as peripheral neuropathy, and its role, if any, in the treatment of other disorders of corneal sensitivity and/or tear production."
Several authors reported the filing of a provisional patent on the use of opioid antagonists to treat dry eye.
Full Text (subscription or payment may be required)
Sign up for our free enewsletters to stay up-to-date in your area of practice - or take a look at an archive of prior issues
Join our CESaver program to earn up to 100 contact hours for only $34.95
Explore a world of online resources
Back to Top